Keogh RJ, Barr MP, Keogh A, McMahon D, O’Brien C, Finn SP, et al. Genomic landscape of NSCLC in the Republic of Ireland. JTO Clin Res Rep. 2024;5(2):100627.

PubMed  Google Scholar 

Shi Y, Au JSK, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skov BG, Høgdall E, Clementsen P, Krasnik M, Larsen KR, Sørensen JB, et al. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. APMIS. 2015;123(2):108–15.

Article  CAS  PubMed  Google Scholar 

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.

Article  CAS  PubMed  Google Scholar 

Ferro A, Marinato GM, Mulargiu C, Marino M, Pasello G, Guarneri V, et al. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. Crit Rev Oncol Hematol. 2024;196:104295.

Article  PubMed  Google Scholar 

Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391(16):1486–98.

Article  CAS  PubMed  Google Scholar 

Planchard D, Jänne PA, Cheng Y, Yang JCH, Yanagitani N, Kim SW, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935–48.

Article  CAS  PubMed  Google Scholar 

Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597(7878):732–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jänne PA, Kobayashi K, Robichaux J, Lee CK, Sugawara S, Yang TY, et al. Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and ontreatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed. Cancer Res. 2024;84(7_Suppl):CT017.

Article  Google Scholar 

Yang JCH, Kim YJ, Lee S-H, Liu B, Ostapenko YV, et al. 4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA stud. J Thorac Oncol. 2025;20(3 Suppl. 1):S6-8.

Article  Google Scholar 

Yang Y, Fan S. Small cell lung cancer transformations from non-small cell lung cancer: biological mechanism and clinical relevance. Chin Med J Pulm Crit Care Med. 2024;2(1):42–7.

Article  PubMed  PubMed Central  Google Scholar 

Cheng Z, Cui H, Wang Y, Yang J, Lin C, Shi X, et al. The advance of the third-generation EGFR-TKI in the treatment of non-small cell lung cancer (review). Oncol Rep. 2023;51(1):16.

Article  PubMed  PubMed Central  Google Scholar 

Lee SH, Cho BC, Hayashi H, Felip E, Spira AI, Girard N, et al. OA02.05 Lazertinib vs osimertinib in 1L EGFR-mutant advanced NSCLC: a randomized, double-blind, exploratory analysis from MARIPOSA. J Thorac Oncol. 2024;19(10):S12.

Article  Google Scholar 

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339–57.

Article  CAS  PubMed  Google Scholar 

Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, et al. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as secondline targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10–16) BOOSTER trial. Ann Oncol. 2022;33(2):181–92.

Article  CAS  PubMed  Google Scholar 

Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study. Cancer Cell. 2021;39(9):1279-91.e3.

Article  CAS  PubMed  Google Scholar 

Ramalingam SS, Cheng Y, Zhou C, Ohe Y, Imamura F, Cho BC, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:viii740.

Article  Google Scholar 

Sun F, Neal JW, Myall NJ. FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases. Transl Cancer Res. 2025;14(6):3295–301.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Planchard D, Janne P, Kobayashi K, Yang JCH, Liu Y. PL02.06 First-line osimertinib + chemotherapy versus osimertinib monotherapy in EGFRm advanced NSCLC: FLAURA2 final overall survival. J Thorac Oncol. 2025;20(10 Suppl. 1):S1.

Article  Google Scholar 

Valdiviezo N, Okamoto I, Hughes BGM, Ahmed S, Wu L, Hu J, et al. 4O Firstline (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes. ESMO Open. 2024;9:102583.

Article  Google Scholar 

Li Y, Li C, Zhao X, Li Y, He F, Pan Z. Aumolertinib plus chemotherapy as firstline treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial. Oncologist. 2025;30(3):oyae336.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang JCH, Lu S, Hayashi H, Felip E, Spira AI, Girard N, et al. Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC. N Engl J Med. 2025;393(17):1681–93.

Article  CAS  PubMed  Google Scholar 

Felip E, Cho BC, Gutiérrez V, Alip A, Besse B, Lu S, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol. 2024;35(9):805–16.

Article  CAS  PubMed  Google Scholar 

Spira AI, Paz-Ares L, Han JY, Shih JY, Mascaux C, Roy UB, et al. Preventing infusion-related reactions with intravenous amivantamab: results from SKIPPirr, a phase 2 study: a brief report. J Thorac Oncol. 2025;20(6):809–16.

Article  CAS  PubMed  Google Scholar 

Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, et al. Subcutaneous versus intravenous aivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated nonsmall cell lung cancer: primary results from the phase III PALOMA-3 study. J Clin Oncol. 2024;42(30):3593–605.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Q, Liu H, Meng S, Jiang T, Li X, Liang S, et al. First-line continual EGFRTKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. J Cancer. 2019;10(2):522.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Besse B, Lee SH, Lu S, Stroyakovskiy D, Yazici O, Rodriguez Cid JR, et al. LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: an early analysis from the phase III MARIPOSA study. Ann Oncol. 2024;35:S1245–6.

Article  Google Scholar 

Lee CK, Robichaux JP, Jänne PA, Kim S-W, Kim TM, et al. 514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: preliminary data from FLAURA2. Ann Oncol. 2023;34(Suppl. 4):S1669–70.

Article  Google Scholar 

Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer. J Natl Cancer Inst. 2022;115(6):742.

Article  Google Scholar 

Wrona A, Dziadziuszko R, Jassem J. Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and antiangiogenic agents. Transl Lung Cancer Res. 2021;10(4):2032–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Q, Zhou F, Liu H, Jiang T, Li X, Xu Y, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR TKIs. J Thorac Oncol. 2018;13(9):1383–92.

Article  PubMed